Lifecore Biomedical, Inc. \De\ (LFCR) Liabilities and Shareholders Equity (2016 - 2025)
Lifecore Biomedical, Inc. \De\ has reported Liabilities and Shareholders Equity over the past 15 years, most recently at $239.3 million for Q2 2025.
- Quarterly results put Liabilities and Shareholders Equity at $239.3 million for Q2 2025, down 5.76% from a year ago — trailing twelve months through May 2025 was $979.2 million (down 1.25% YoY), and the annual figure for FY2025 was $239.3 million, down 5.76%.
- Liabilities and Shareholders Equity for Q2 2025 was $239.3 million at Lifecore Biomedical, Inc. \De\, up from $237.7 million in the prior quarter.
- Over the last five years, Liabilities and Shareholders Equity for LFCR hit a ceiling of $506.9 million in Q1 2021 and a floor of $236.7 million in Q1 2023.
- Median Liabilities and Shareholders Equity over the past 5 years was $254.7 million (2024), compared with a mean of $304.3 million.
- Biggest five-year swings in Liabilities and Shareholders Equity: soared 71.0% in 2021 and later plummeted 45.27% in 2022.
- Lifecore Biomedical, Inc. \De\'s Liabilities and Shareholders Equity stood at $421.3 million in 2021, then crashed by 34.5% to $276.0 million in 2022, then fell by 10.93% to $245.8 million in 2023, then rose by 3.89% to $255.4 million in 2024, then decreased by 6.28% to $239.3 million in 2025.
- The last three reported values for Liabilities and Shareholders Equity were $239.3 million (Q2 2025), $237.7 million (Q1 2025), and $255.4 million (Q4 2024) per Business Quant data.